Ultragenyx (RARE) Financials & Stock Activity Analysis

Font: Financial Modeling Prep  • May 24, 2026

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE): Analyzing Key Financials and Recent Stock Activity

• Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company, is dedicated to developing treatments for rare genetic diseases, strategically using inducement grants to attract and retain top talent.
• Despite a recent insider stock sale, the analyst firm Cantor Fitzgerald maintained an "Overweight" rating on Ultragenyx Pharmaceutical Inc., signaling continued confidence in its market outlook.
• Key financial metrics for Ultragenyx Pharmaceutical Inc. include a negative Price-to-Earnings (P/E) ratio of -3.86, a Price-to-Sales ratio of 3.44, and a robust current ratio of 2.02, indicating strong short-term liquidity.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is a biopharmaceutical company. It focuses on developing and selling new treatments for serious rare and ultra-rare genetic diseases. The company aims to provide therapies for patients who have few or no other treatment options available to them.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) recently reported an inducement grant of 17,567 restricted stock units. These were given to 11 newly hired non-executive employees. This type of grant is a common tool companies use to attract and retain new talent, aligning employee interests with the company's long-term performance.

The awards were approved by the company's compensation committee. The stock units will vest over four years, with 25% becoming available each year. This is dependent on the employees staying with the company. In a separate transaction, a director, SULIMAN SHEHNAAZ, sold 5,740 shares for a total of $144,189.00.

Despite the insider sale, the analyst firm Cantor Fitzgerald maintained its "Overweight" rating on Ultragenyx Pharmaceutical Inc. The stock price was $23.37 at the time. The company's financial data shows a Price-to-Earnings (P/E) ratio of -3.86. A negative P/E ratio indicates that the company has had negative earnings over the past year.

Other financial metrics show a Price-to-Sales ratio of 3.44 and a negative Enterprise Value to Operating Cash Flow of -6.70. This suggests Ultragenyx Pharmaceutical Inc. is spending more cash on its operations than it generates. However, its current ratio is 2.02, showing it has enough short-term assets to cover its short-term liabilities.